Brief: Mannkind Announces First Patient Enrolled In Inhale-1St Pediatric Study Evaluating Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (T1d)
09/02/2026 11:13
Feb 9 (Reuters) - MannKind Corp MNKD.O: MANNKIND ANNOUNCES FIRST PATIENT ENROLLED IN INHALE-1ST PEDIATRIC STUDY EVALUATING AFREZZA® FOR YOUTH WITH NEWLY-DIAGNOSED TYPE 1 DIABETES (T1D) Source text: ID:nGNX1LdkSJ Further company coverage: MNKD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children